SEC Info - International Isotopes Inc.

Page	(sequential)		(alphabetic)	↑Top
		Alternative Formats (Word, et al.) Controls and Procedures Exhibits Legal Proceedings Management's Discussion and Analysis of Financial Condition and Results of Operations Notes to Unaudited Condensed Consolidated Financial Statements Risk Factors Signatures Unaudited Condensed Consolidated Balance Sheets at September 30, 2022 and December 31, 2021 Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021 Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2022 and 2021 Unaudited Statement of Reconciliation of Stockholder's (Deficit) Equity for the Three and Nine Months Ended September 30, 2022 and 2021 Unregistered Sales of Equity Securities and Use of Proceeds
1	1st Page – Filing Submission
"	Unaudited Condensed Consolidated Balance Sheets at September 30, 2022 and December 31, 2021
"	Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2022 and 2021
"	Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021
"	Unaudited Statement of Reconciliation of Stockholder's (Deficit) Equity for the Three and Nine Months Ended September 30, 2022 and 2021
"	Notes to Unaudited Condensed Consolidated Financial Statements
"	Management's Discussion and Analysis of Financial Condition and Results of Operations
"	Controls and Procedures
"	Legal Proceedings
"	Risk Factors
"	Unregistered Sales of Equity Securities and Use of Proceeds
"	Exhibits
"	Signatures

i 0001038277 i false i Q3 i 2022 i --12-31 i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i P5Y i i i 0001038277 2022-01-01 2022-09-30 0001038277 2022-11-11 0001038277 2022-09-30 0001038277 2021-12-31 0001038277 2022-07-01 2022-09-30 0001038277 2021-07-01 2021-09-30 0001038277 2021-01-01 2021-09-30 0001038277 2020-12-31 0001038277 2021-09-30 0001038277 us-gaap:CommonStockMember 2021-12-31 0001038277 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001038277 us-gaap:RetainedEarningsMember 2021-12-31 0001038277 us-gaap:ParentMember 2021-12-31 0001038277 us-gaap:CommonStockMember 2022-06-30 0001038277 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001038277 us-gaap:RetainedEarningsMember 2022-06-30 0001038277 us-gaap:ParentMember 2022-06-30 0001038277 2022-06-30 0001038277 us-gaap:CommonStockMember 2020-12-31 0001038277 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001038277 us-gaap:RetainedEarningsMember 2020-12-31 0001038277 us-gaap:ParentMember 2020-12-31 0001038277 us-gaap:NoncontrollingInterestMember 2020-12-31 0001038277 us-gaap:CommonStockMember 2021-06-30 0001038277 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001038277 us-gaap:RetainedEarningsMember 2021-06-30 0001038277 us-gaap:ParentMember 2021-06-30 0001038277 us-gaap:NoncontrollingInterestMember 2021-06-30 0001038277 2021-06-30 0001038277 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001038277 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001038277 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001038277 us-gaap:ParentMember 2022-01-01 2022-09-30 0001038277 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001038277 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001038277 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001038277 us-gaap:ParentMember 2022-07-01 2022-09-30 0001038277 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001038277 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001038277 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001038277 us-gaap:ParentMember 2021-01-01 2021-09-30 0001038277 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-09-30 0001038277 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001038277 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001038277 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001038277 us-gaap:ParentMember 2021-07-01 2021-09-30 0001038277 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001038277 us-gaap:CommonStockMember 2022-09-30 0001038277 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001038277 us-gaap:RetainedEarningsMember 2022-09-30 0001038277 us-gaap:ParentMember 2022-09-30 0001038277 us-gaap:CommonStockMember 2021-09-30 0001038277 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001038277 us-gaap:RetainedEarningsMember 2021-09-30 0001038277 us-gaap:ParentMember 2021-09-30 0001038277 us-gaap:NoncontrollingInterestMember 2021-09-30 0001038277 inis:RadQualLlcMember srt:AffiliatedEntityMember 2017-08-31 0001038277 inis:RadQualLlcMember 2021-07-08 0001038277 us-gaap:StockOptionMember 2022-01-01 2022-09-30 0001038277 us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-09-30 0001038277 us-gaap:StockOptionMember 2022-07-01 2022-09-30 0001038277 us-gaap:SeriesCPreferredStockMember 2022-07-01 2022-09-30 0001038277 us-gaap:StockOptionMember 2021-07-01 2021-09-30 0001038277 us-gaap:StockOptionMember 2021-01-01 2021-09-30 0001038277 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001038277 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-09-30 0001038277 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-09-30 0001038277 inis:EffectOfDilutiveSecuritiesStockOptionsMember 2022-07-01 2022-09-30 0001038277 inis:EffectOfDilutiveSecuritiesStockOptionsMember 2021-07-01 2021-09-30 0001038277 inis:EffectOfDilutiveSecuritiesStockOptionsMember 2022-01-01 2022-09-30 0001038277 inis:EffectOfDilutiveSecuritiesStockOptionsMember 2021-01-01 2021-09-30 0001038277 us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-09-30 0001038277 inis:ThePurchaseAgreementMember 2021-07-07 2021-07-08 0001038277 inis:ThePurchaseAgreementMember 2021-07-08 0001038277 2022-02-01 2022-02-28 0001038277 inis:RadiochemicalProductsMember 2022-09-30 0001038277 inis:RadiochemicalProductsMember 2021-12-31 0001038277 inis:CobaltProductsMember 2022-09-30 0001038277 inis:CobaltProductsMember 2021-12-31 0001038277 inis:NuclearMedicineProductsMember 2022-09-30 0001038277 inis:NuclearMedicineProductsMember 2021-12-31 0001038277 inis:EmployeeStockOwnershipMember 2022-01-01 2022-09-30 0001038277 inis:EmployeeStockOwnershipMember 2021-01-01 2021-09-30 0001038277 inis:EmployeeStockOwnershipMember 2022-09-30 0001038277 inis:IncentivePlan2015Member 2018-07-01 2018-07-31 0001038277 inis:IncentivePlan2015Member 2022-09-30 0001038277 inis:QualifiedStockOptionsMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-01-01 2022-09-30 0001038277 inis:QualifiedStockOptionsMember inis:ShareBasedPaymentArrangementEmployeeTwoMember 2022-01-01 2022-09-30 0001038277 inis:QualifiedStockOptionsMember srt:ExecutiveOfficerMember 2022-02-01 2022-02-21 0001038277 inis:NonQualifiedStockOptionsMember srt:DirectorMember 2022-02-01 2022-02-21 0001038277 inis:NonQualifiedStockOptionsMember 2022-01-01 2022-09-30 0001038277 inis:QualifiedStockOptionsMember 2022-01-01 2022-09-30 0001038277 inis:QualifiedStockOptionsMember srt:MinimumMember 2022-01-01 2022-09-30 0001038277 inis:NonQualifiedStockOptionsMember srt:MinimumMember 2022-01-01 2022-09-30 0001038277 inis:QualifiedStockOptionsMember srt:MaximumMember 2022-01-01 2022-09-30 0001038277 inis:NonQualifiedStockOptionsMember srt:MaximumMember 2022-01-01 2022-09-30 0001038277 inis:QualifiedStockOptionsMember 2022-03-01 2022-03-31 0001038277 inis:QualifiedStockOptionsMember 2022-08-01 2022-08-31 0001038277 inis:IncentivePlan2015Member srt:ChiefExecutiveOfficerMember 2022-02-01 2022-02-28 0001038277 inis:IncentivePlan2015Member srt:ChiefExecutiveOfficerMember 2022-02-28 0001038277 inis:ClassmWarrantsMember 2022-02-01 2022-02-14 0001038277 inis:ClassmWarrantsMember 2022-02-14 0001038277 inis:ClassmWarrantsMember 2022-02-01 2022-02-17 0001038277 inis:ClassnWarrantsMember 2022-05-01 2022-05-12 0001038277 inis:ClassmWarrantsMember 2021-09-30 0001038277 inis:ClassnWarrantsMember 2022-05-12 0001038277 us-gaap:SeriesBPreferredStockMember 2022-05-31 0001038277 us-gaap:SeriesCPreferredStockMember 2022-09-30 0001038277 inis:PromissoryNote2013Member inis:FormerChairmanOfTheBoardMember 2013-12-31 0001038277 inis:PromissoryNote2013Member inis:FormerChairmanOfTheBoardMember 2013-01-01 2013-12-31 0001038277 inis:PromissoryNote2013Member inis:FormerChairmanOfTheBoardMember 2019-01-01 2019-12-31 0001038277 inis:PromissoryNote2013Member inis:FormerChairmanOfTheBoardMember 2022-01-01 2022-03-31 0001038277 inis:PromissoryNote2013Member inis:FormerChairmanOfTheBoardMember 2022-09-30 0001038277 inis:PromissoryNote2018Member srt:ChiefExecutiveOfficerMember 2018-04-30 0001038277 inis:PromissoryNote2018Member srt:ChiefExecutiveOfficerMember 2018-04-01 2018-04-30 0001038277 inis:PromissoryNote2018Member srt:ChiefExecutiveOfficerMember 2018-06-01 2018-06-30 0001038277 inis:PromissoryNote2018Member srt:ChiefExecutiveOfficerMember 2019-02-01 2019-02-28 0001038277 inis:PromissoryNote2018Member srt:ChiefExecutiveOfficerMember 2019-07-01 2019-07-31 0001038277 inis:PromissoryNote2018Member srt:ChiefExecutiveOfficerMember 2019-12-01 2019-12-31 0001038277 inis:PromissoryNote2018Member srt:ChiefExecutiveOfficerMember 2021-12-01 2021-12-31 0001038277 inis:PromissoryNote2018Member srt:ChiefExecutiveOfficerMember 2022-09-30 0001038277 inis:PromissoryNote2019Member inis:MajorShareholdersMember 2019-12-20 0001038277 inis:PromissoryNote2019Member inis:MajorShareholdersMember 2019-12-01 2019-12-31 0001038277 inis:PromissoryNote2019Member inis:MajorShareholdersMember 2019-12-21 2019-12-31 0001038277 inis:PromissoryNote2019Member inis:MajorShareholdersMember 2022-09-30 0001038277 inis:PromissoryNote2019Member inis:MajorShareholdersMember 2022-01-01 2022-09-30 0001038277 inis:PromissoryNoteApril2021Member srt:ChiefExecutiveOfficerMember 2021-04-30 0001038277 inis:PromissoryNoteApril2021Member srt:ChiefExecutiveOfficerMember 2021-04-01 2021-04-30 0001038277 inis:PromissoryNoteApril2021Member srt:ChiefExecutiveOfficerMember 2022-01-01 2022-03-31 0001038277 2014-10-01 2014-10-31 0001038277 2011-08-01 2011-08-31 0001038277 inis:RadiochemicalProductsMember country:US 2022-07-01 2022-09-30 0001038277 inis:RadiochemicalProductsMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001038277 inis:RadiochemicalProductsMember 2022-07-01 2022-09-30 0001038277 inis:RadiochemicalProductsMember country:US 2021-07-01 2021-09-30 0001038277 inis:RadiochemicalProductsMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0001038277 inis:RadiochemicalProductsMember 2021-07-01 2021-09-30 0001038277 inis:CobaltProductsMember country:US 2022-07-01 2022-09-30 0001038277 inis:CobaltProductsMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001038277 inis:CobaltProductsMember 2022-07-01 2022-09-30 0001038277 inis:CobaltProductsMember country:US 2021-07-01 2021-09-30 0001038277 inis:CobaltProductsMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0001038277 inis:CobaltProductsMember 2021-07-01 2021-09-30 0001038277 inis:NuclearMedicineProductsMember country:US 2022-07-01 2022-09-30 0001038277 inis:NuclearMedicineProductsMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001038277 inis:NuclearMedicineProductsMember 2022-07-01 2022-09-30 0001038277 inis:NuclearMedicineProductsMember country:US 2021-07-01 2021-09-30 0001038277 inis:NuclearMedicineProductsMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0001038277 inis:NuclearMedicineProductsMember 2021-07-01 2021-09-30 0001038277 inis:FluorineProductsMember country:US 2022-07-01 2022-09-30 0001038277 inis:FluorineProductsMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001038277 inis:FluorineProductsMember 2022-07-01 2022-09-30 0001038277 inis:FluorineProductsMember country:US 2021-07-01 2021-09-30 0001038277 inis:FluorineProductsMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0001038277 inis:FluorineProductsMember 2021-07-01 2021-09-30 0001038277 country:US 2022-07-01 2022-09-30 0001038277 us-gaap:NonUsMember 2022-07-01 2022-09-30 0001038277 country:US 2021-07-01 2021-09-30 0001038277 us-gaap:NonUsMember 2021-07-01 2021-09-30 0001038277 inis:RadiochemicalProductsMember country:US 2022-01-01 2022-09-30 0001038277 inis:RadiochemicalProductsMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001038277 inis:RadiochemicalProductsMember 2022-01-01 2022-09-30 0001038277 inis:RadiochemicalProductsMember country:US 2021-01-01 2021-09-30 0001038277 inis:RadiochemicalProductsMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0001038277 inis:RadiochemicalProductsMember 2021-01-01 2021-09-30 0001038277 inis:CobaltProductsMember country:US 2022-01-01 2022-09-30 0001038277 inis:CobaltProductsMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001038277 inis:CobaltProductsMember 2022-01-01 2022-09-30 0001038277 inis:CobaltProductsMember country:US 2021-01-01 2021-09-30 0001038277 inis:CobaltProductsMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0001038277 inis:CobaltProductsMember 2021-01-01 2021-09-30 0001038277 inis:NuclearMedicineProductsMember country:US 2022-01-01 2022-09-30 0001038277 inis:NuclearMedicineProductsMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001038277 inis:NuclearMedicineProductsMember 2022-01-01 2022-09-30 0001038277 inis:NuclearMedicineProductsMember country:US 2021-01-01 2021-09-30 0001038277 inis:NuclearMedicineProductsMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0001038277 inis:NuclearMedicineProductsMember 2021-01-01 2021-09-30 0001038277 inis:FluorineProductsMember country:US 2022-01-01 2022-09-30 0001038277 inis:FluorineProductsMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001038277 inis:FluorineProductsMember 2022-01-01 2022-09-30 0001038277 inis:FluorineProductsMember country:US 2021-01-01 2021-09-30 0001038277 inis:FluorineProductsMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0001038277 inis:FluorineProductsMember 2021-01-01 2021-09-30 0001038277 country:US 2022-01-01 2022-09-30 0001038277 us-gaap:NonUsMember 2022-01-01 2022-09-30 0001038277 country:US 2021-01-01 2021-09-30 0001038277 us-gaap:NonUsMember 2021-01-01 2021-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:RadiochemicalProductsMember 2022-07-01 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:RadiochemicalProductsMember 2021-07-01 2021-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:RadiochemicalProductsMember 2022-01-01 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:RadiochemicalProductsMember 2021-01-01 2021-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:CobaltProductsMember 2022-07-01 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:CobaltProductsMember 2021-07-01 2021-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:CobaltProductsMember 2022-01-01 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:CobaltProductsMember 2021-01-01 2021-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:NuclearMedicineProductsMember 2022-07-01 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:NuclearMedicineProductsMember 2021-07-01 2021-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:NuclearMedicineProductsMember 2022-01-01 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:NuclearMedicineProductsMember 2021-01-01 2021-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:FluorineProductsMember 2022-07-01 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:FluorineProductsMember 2021-07-01 2021-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:FluorineProductsMember 2022-01-01 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:FluorineProductsMember 2021-01-01 2021-09-30 0001038277 us-gaap:OperatingSegmentsMember 2022-07-01 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0001038277 us-gaap:OperatingSegmentsMember 2022-01-01 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember 2021-01-01 2021-09-30 0001038277 us-gaap:MaterialReconcilingItemsMember 2022-07-01 2022-09-30 0001038277 us-gaap:MaterialReconcilingItemsMember 2021-07-01 2021-09-30 0001038277 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-09-30 0001038277 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:RadiochemicalProductsMember 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:RadiochemicalProductsMember 2021-12-31 0001038277 us-gaap:OperatingSegmentsMember inis:CobaltProductsMember 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:CobaltProductsMember 2021-12-31 0001038277 us-gaap:OperatingSegmentsMember inis:NuclearMedicineProductsMember 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:NuclearMedicineProductsMember 2021-12-31 0001038277 us-gaap:OperatingSegmentsMember inis:FluorineProductsMember 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember inis:FluorineProductsMember 2021-12-31 0001038277 us-gaap:OperatingSegmentsMember 2022-09-30 0001038277 us-gaap:OperatingSegmentsMember 2021-12-31 0001038277 us-gaap:MaterialReconcilingItemsMember 2022-09-30 0001038277 us-gaap:MaterialReconcilingItemsMember 2021-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure inis:Number

i x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

i o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ý i Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ý i Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes ý i No

As of November 11, 2022, the number of shares of common stock, $0.01 par value, outstanding was i 514,889,916.

See accompanying notes to the unaudited condensed consolidated financial statements.

Reconciliation of cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows is presented in the table below:

See accompanying notes to the unaudited condensed consolidated financial statements.

See accompanying notes to the unaudited condensed consolidated financial statements

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding industry prospects and future results of operations or financial position, made in this Quarterly Report are forward-looking statements. Words such as “anticipates,” “believes,” “should,” “expects,” “future,” “intends” and similar expressions identify forward-looking statements. Forward-looking statements reflect management’s current expectations, plans or projections, and are inherently uncertain. Actual results could differ materially from management's expectations, plans or projections. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. Certain risks and uncertainties that could cause our actual results to differ significantly from management’s expectations are described in the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 31, 2022 and in the other reports we file with the SEC. These factors describe some but not all of the factors that could cause actual results to differ significantly from management’s expectations. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by applicable law. Readers are urged, however, to review the risks and other factors set forth in the reports that we file from time to time with the SEC.

International Isotopes Inc., its wholly owned subsidiaries, including RadQual, LLC and TI Services, LLC (collectively, the Company, we, our, or us) manufacture a full range of nuclear medicine calibration and reference standards, manufacture a range of cobalt products, and distribute sodium iodide I-131 as a generic drug. We own 100% interest of RadQual, LLC (RadQual), a global supplier of molecular imaging quality control and calibration devices.

On July 8, 2021, we entered into a Membership Interest Purchase Agreement (the Purchase Agreement) with RadQual and the sellers set forth in the Purchase Agreement, which included our Chairman of the Board, Chief Executive Officer, former Chairman of the Board, and certain other stockholders of the Company (collectively, the Sellers). Pursuant to the Purchase Agreement, we acquired all of the outstanding membership interests of RadQual not then-owned by the Company for an aggregate purchase price of approximately $4.4 million, payable in shares of our common stock valued at $0.11 per share (determined by the average trading price of our common stock on the OTC Markets during the 60 trading day period immediately prior to June 2, 2021) (the RadQual Acquisition). We issued an aggregate of 40,176,236 shares of its common stock to the Sellers as consideration in the RadQual Acquisition. Prior to the RadQual Acquisition, we owned approximately 24.5% of the outstanding membership interests of RadQual, and after acquiring all of the remaining membership interests of RadQual, RadQual became a wholly-owned subsidiary of the Company. The RadQual Acquisition closed on July 8, 2021.

Our business consists of the following four business segments in 2022 and consisted of five business segments in 2021:

Nuclear Medicine Standards. Our Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. These sources are used for indication of patient positioning, SPECT and PET camera operational testing, and calibration of dose measurement equipment. Revenue from nuclear medicine products includes consolidated sales from TI Services, LLC (TI Services), a joint venture that we formed with RadQual in December 2010 to distribute our products. Our nuclear medicine standards products include a host of specially designed items used in the nuclear medicine industry. In addition to the manufacture of these products, we have developed a complete line of specialty packaging for the safe transport and handling of these products. Beginning January 1, 2022, this segment also includes miscellaneous source disposal activities that were previously reported as part of the Radiological Services segment.

Cobalt Products. Our Cobalt Products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for radiation therapy and various industrial applications, and recycling of expended cobalt sources. We are the only company in the U.S. that can provide all these unique services. There has been a significant increase in regulation by the Nuclear Regulatory Commission (NRC) in recent years that has created a significant barrier to new entrants into this market. The Company has a contract in place with the U.S. Department of Energy (DOE) for the production of high specific activity cobalt in the Advanced Test Reactor (ATR) in Idaho. This agreement will be in effect until October 2024.

Radiochemical Products. Our Radiochemical Products segment includes production and distribution and FDA approved generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and carcinoma of the thyroid. We are the only U.S. Company distributing this generic drug product. This segment also includes distribution of certain other radiochemical products and contract manufacturing of radiopharmaceutical products for our customers.

Fluorine Products. We established the Fluorine Products segment in 2004 to support production and sale of the gases that we expected to produce using our Fluorine Extraction Process (FEP) in conjunction with the operation of the proposed depleted uranium de-conversion facility in Lea County, New Mexico. Near the end of 2013, due to changes in the nuclear industry, we placed further engineering work on this project on hold. We continue to hold discussions with potential future customers seeking this type of service, however, further development activity within this segment will be deferred until market and industry conditions change to justify resuming design and construction of the facility. In the meantime, the Company expects to continue to incur some costs associated with the maintenance of licenses and other necessary project investments, and to continue to keep certain agreements in place that will support resumption of project activities at the appropriate time.

Radiological Services. Our Radiological Services segment consisted of a wide variety of miscellaneous services such as decommissioning disused irradiation units, performing sealed source exchanges in irradiation and therapy units, and gemstone processing. The Company has suspended all of its field service activities and has terminated most gemstone processing. Due to decreased activity in this segment, starting January 1, 2022, this segment was reorganized into our Nuclear Medicine Standards segment. Additionally, we reclassified our reporting for 2021 to include all activities for the Radiological Services business segment under the Nuclear Medicine Standards segment.

As a result of the COVID-19 pandemic, we experienced a reduction of sales within our nuclear medicine calibration standards segment and radiochemicals segment during 2021. There was no discernable impact from COVID-19 to our cobalt products business segment during the period. The decrease in sales for 2021 for our nuclear medicine calibration standards segment was the result of the temporary closure of many imaging clinics and suspension of elective or non-essential imaging procedures. During the three months ended March 31, 2022, we experienced some global shipping disruption that were partially attributable to the COVID-19 pandemic. The decrease in sales in our nuclear medicine calibration standards segment for the nine months ended September 30, 2022, is partially due to these shipping disruptions.

To-date we have not furloughed or terminated any employees as a result of the financial impact of COVID-19. We have only seen a limited impact in our raw material supply chain related to the COVID-19. From the beginning of 2022, we have experienced an increase in costs for many raw materials and production supplies due to recent cost inflation which have led to increases to costs of goods sold and operating expenses. Although, all segments have been impacted from these cost increases, our nuclear medicine calibration standards segment has been impacted the most. We have seen these increased costs stabilize somewhat; and we are working on counteracting these cost increases with an increase to our produce prices. We believe we can increase our sales prices enough to overcome these cost increases while continuing to maintain and grow our sales.

Revenue for the three months ended September 30, 2022 was $2,789,273 as compared to $2,617,514 for the same period in 2021, an overall increase of $171,759, or approximately 7%. This increase in revenue was the result of increased revenue in our Radiochemical Products, Cobalt Products, and Nuclear Medicine Standards segments, as discussed in detail below.

The following table presents a period-to-period comparison of total revenue by segment for the three months ended September 30, 2022 and 2021:

Cost of sales increased to $1,305,730 for the three months ended September 30, 2022 from $1,006,334 for the same period in 2021. This is an increase of $299,396, or approximately 30%. The increase in cost of sales in the three-month comparison was primarily due to the increased sales activity in all our business segments along with increases in the cost of raw materials and supplies driven by recent cost inflation, as discussed in detail below. Gross profit for the three months ended September 30, 2022 was $1,483,543, compared to $1,611,180 for the same period in 2021. This represents a decrease in gross profit of $127,637, or approximately 8%. Our Gross profit percentage for the three months ended September 30, 2022 was 53%, compared to 62% for the same period in 2021. This decrease in gross profit percentage is a result of increased cost in raw material and supplies driven by recent cost inflation, as discussed in detail below.

The following table presents cost of sales and gross profit data for each of our business segments for the three months ended September 30, 2022 and 2021:

Operating expense increased approximately 22% to $1,957,096 for the three months ended September 30, 2022, from $1,609,758 for the same period in 2021. This increase of $347,338, is due to an increase of 23% in Salaries and Contract Labor expense, and increase of 14% in General, Administrative, and Consulting expenses, and a 101% increase in Research and Development costs. The increase in Salaries and Contract Labor costs is a result of an increased number of employees and increases to labor rates incurred during the three months ended September 30, 2022, as compared to the same period in 2021. The increase in General, Administrative, and Consulting expenses is due to periodic waste disposal costs that occurred in the three months ended September 30, 2022. The 101% increase in Research and Development cost is due to increased activity in product development during the three months ended September 30, 2022, as compared to the same period in 2021.

The following table presents a comparison of total operating expense for the three months ended September 30, 2022 and 2021:

Other income was $49,151 for the three months ended September 30, 2022, as compared to $54,083 for the same period in 2021. This is a decrease of $4,932, or approximately 9%. In September 2022, we experienced a fraudulent transactions incident. The fraudulent charges totaled approximately $85,000. These charges were recorded as “other expense”. Investigations by our bank and by law enforcement are ongoing. There have been no indications of any involvement within our Company. As we expected to recoup all fraudulent changes from our bank, for the three months ending September 30, 2022, we recognized "other income" to offset the fraudulent charges recorded under “other expense”. In October and November 2022, we recovered all of the fraudulent charges from our bank.

Interest expense for the three months ended September 30, 2022 was $147,116, compared to $191,544 for the same period in 2021. This is a decrease of $44,428, or approximately 23%. Interest expense includes dividends accrued on our Series C Redeemable Convertible Preferred Stock (Series C Preferred Stock). As discussed below, we issued Series C Preferred Stock in February 2017 and May 2017. For the three months ended September 30, 2022, we accrued dividends payable of $60,945, which have been recorded as interest expense. Additionally, non-cash interest expense in the amount of $26,548 for the

accretion of the beneficial conversion feature of the 2019 Promissory Note (as defined below) and $37,518 for the issuance of warrants in conjunction with the 2019 Promissory Note were recorded for the three months ended September 30, 2022. See Note 7 “Debt” to our unaudited consolidated financial statements in this Quarterly Report for additional information about our indebtedness and the associated interest expense.

Our net loss for the three months ended September 30, 2022, was $568,669, compared to net loss of $136,869, for the same period in 2021. This is an increase in loss of $431,800 is largely the result of the increase in Cost of Sales in our Cobalt products and Nuclear Medicine Standards segments to the increase in operating expenses for the three months ended September 30, 2022, as compared to the same period in 2021.

Radiochemical Products. Revenue from the sale of Radiochemical Products for the three months ended September 30, 2022 was $1,298,667, compared to $1,210,615 for the same period in 2021. This is an increase of $88,052, or approximately 7% during the three months ended September 30, 2022. The increase is the result of continued increased sales of our generic sodium iodide I-131 drug product. We expect continued sales growth for our Radiochemical products going forward.

Cost of sales for Radiochemical Products increased to $498,210 for the three months ended September 30, 2022, as compared to $459,344 for the same period in 2021. This is an increase of $38,866, or approximately 8%, and was the result of increased sales of product. Gross profit of radiochemical products for the three months ended September 30, 2022 was $800,457, compared to $751,271, for the same period in 2021. Gross profit percentage was approximately 62% for the three months ended September 30 for both 2022 and 2021. Operating expense for this segment decreased to $346,234 for the three months ended September 30, 2022, compared to $380,684 for the same period in 2021. This decrease in operating expense of $34,450, or approximately 10%, was primarily due to decreased costs for production supplies, and depreciation expense. This segment reported net income of $454,223 for the three months ended September 30, 2022, as compared to net income of $370,586 for the same period in 2021. The increase in net income of $83,637 is the result of the increase in revenue.

Cobalt Products. Revenue from the sale of Cobalt Products for the three months ended September 30, 2022 was $424,731, compared to $408,808, for the same period in 2021. This represents an increase of $15,923, or approximately 4%. The increase was primarily due to the timing of cobalt sealed source manufacturing sales. Large value sales of high activity cobalt sources occur at somewhat random times throughout the year. Frequently the timing of these sales can have a significant impact on period over period comparisons.

In October 2014, we entered into a ten-year agreement with the DOE for the irradiation of cobalt targets. It takes many years to irradiate these cobalt targets to the desired level of activity and we anticipated having high specific activity cobalt available for our customers in 2020. However, the material had lower than expected activity and further receipt of material was delayed until about June 2021. At that point the material still had lower than expected activity, and we reached an agreement with the DOE to purchase the material at a discounted rate. Periodically we have been able to acquire recycled material that can be used to manufacture sealed sources for customers, and in some instances, our customers have supplied their own cobalt material for source fabrication. We also have access to additional low specific activity material produced by the DOE and expect to obtain, process, and sell additional cobalt products as a result during the remainder of 2022.

We have entered into cobalt purchase agreements with several customers. Pursuant to these contracts, we will supply some bulk cobalt-60 and provide sealed source manufacturing for the customers. The terms of these cobalt contracts require some advance progress payments from each customer. The funding received under these contracts has been recorded as unearned revenue under short- and long-term liabilities in our consolidated financial statements. For the three months ended September 30, 2022 and 2021, we recognized approximately $10,000 and $1,500, respectively when we fulfilled contract performance objectives by supplying sealed sources manufactured with cobalt from the ATR or alternate suppliers.

Cost of sales for the three months ended September 30, 2022, was $232,679, as compared to $148,855, for the same period in 2021. Gross profit for cobalt products for the three months ended September 30, 2022, was $192,052 compared to $259,953 for the same period in 2021. This is a decrease of $67,901, or approximately 26% and is attributable to an increased labor and material cost in source manufacturing for the three months ended September 30, 2022, as compared to the same period in 2021. Our gross profit percentages were approximately 45% and 64% for the three-month periods ended September 30, 2022 and 2021, respectively. The decrease in the gross profit percentage for the three months ended September 30, 2022 is primarily due to increased costs of raw material and labor used in the manufacture of sealed sources. Operating expense in this segment increased to $326,096 for the three months ended September 30, 2022, from $93,145 for the same period in 2021. This is an increase of $232,951, or approximately 250%. This increase in operating expenses for the three months ended September 30, 2022 is due to waste disposal expense of approximately $215,000. Our manufacturing processes generate some radioactive waste. The estimated costs of storage and disposal of these materials have been included in the manufacturing and sales price of our products. However, actual disposal costs are subject to change at the discretion of the disposal site and are ultimately applied at the time of disposal. Our net loss for Cobalt Products was $134,044 for the three months ended September 30, 2022, as compared to a net income of $166,808 for the same period in 2021. The decrease in income of $300,852, or approximately 180%, was attributable to an increased cost of materials from cobalt sealed source manufacturing due to recent cost inflation and due to increased operating expenses for waste disposal.

Nuclear Medicine Standards. Revenue from Nuclear Medicine Standards for the three months ended September 30, 2022, was $1,065,875, compared to $990,328 for the same period in 2021. This represents an increase in revenue of $75,547, or approximately 8%.

Cost of sales for our Nuclear Medicine Standards segment for the three months ended September 30, 2022, was $574,841, as compared to $398,135 for the same period in 2021. The increase in cost of sales in the period-to-period comparison of $176,706, or 44%, was due to increased sales activity and increased costs for supplies and raw materials during the three-month period ended September 30, 2022, as compared to the same period in 2021. Gross profit for our nuclear medicine standards segment for the three months ended September 30, 2022 was $491,034 compared to $592,193 for the same period in 2021, and gross profit percentages were approximately 46% and 60% for the three months ended September 30, 2022 and 2021, respectively. This is a decrease in gross profit of $101,159, or approximately 17%. The decrease in gross profit in the period-to-period comparison is primarily the result of increased costs for supplies and raw materials attributable to cost inflation. We expect these increased costs to continue going forward, and we are adjusting our sales prices accordingly.

Operating expense for this segment for the three months ended September 30, 2022 decreased to $425,863, from $459,008 for the same period in 2021. This is a decrease of 33,145, or approximately 7%, and is the result of decreased marketing and consulting fees in the three months ended September 30, 2022. Operating expenses includes non-controlling member interest expense attributable to RadQual and TI Services of $0 for the three months ended September 30, 2022 compared with $4,275 for the three months ended September 30, 2021. In July 2021, we purchased the remaining 75.5% interest in RadQual; this resulted in RadQual and TI Services becoming our fully owned subsidiaries. Net income for this segment for the three months ended September 30, 2022 was $65,171, compared to net income $133,185 for the same period in 2021. This decrease in net income of $68,014, or approximately 51% and is primarily the result of increased costs for supplies and raw materials attributable to cost inflation.

Radiological Services. Starting in 2022, due to drastically decreased activity in the segment, all remaining activities in our Radiological Services is reported in our Nuclear Medicine Standards segment.

In January 2020, we notified our gemstone processing customer that the service contract with them was being terminated because the volume of gemstones sent for processing did not meet contract minimums. The termination activities and wrap up of this service substantially occurred in 2021 and the Company saw a steady decline in revenue from this service as production was wrapped up. In the first half of 2022, we converted the spaces in the facility that were previously used to perform this contract work into expanded Nuclear Medicine new product manufacturing. The loss in revenue expected from termination of the gemstone processing agreement is expected to be more than compensated for by the expansion of new nuclear medicine source products.

Revenue from field service work for the DOE had accounted for the majority of revenue in this segment. However, Radiological Field Services work was terminated in 2020 and we did not generate any Radiological Field Services revenue in 2021 or 2022. We have removed this type of activity from our NRC license and do not expect to perform this in future years.

We continue to engage in source disposal activities and have begun reporting these activities under the Nuclear Medicine Standards segment starting January 1, 2022. Additionally, we reclassified our reporting for 2021 to include all activities for the Radiological Services business segment under the Nuclear Medicine Standards segment.

Fluorine Products. For the three months ended September 30, 2022, we had no revenue for our Fluorine Products segment as compared to $7,763 for the three months ended September 30, 2021. Revenues were related to an agreement to provide engineering and technical assistance services related to our fluorine products intellectual property. The agreement concluded in 2021. During the three months ended September 30, 2022, we incurred $37,204 of expense related to items in support of future planning and design for the proposed de-conversion facility, as compared to $34,348 for the same three-month period in 2021. This is an increase of 8% in the period-to-period comparison and is the result of increased professional services costs related to exploring options for possible renewal of work on this project.

We established the Fluorine Products segment in 2004 to support production and sale of the gases produced using our FEP. The project has been placed on hold since 2013 and we will continue to limit our expenditures to essential items such as maintenance of the NRC license, land use agreements, communication with our prospective FEP product customers, and interface with the State of New Mexico and Lea County officials until such time that we decide to resume the project.

Revenue for the nine-month period ended September 30, 2022 was $8,031,522, as compared to $7,369,922 for the same period in 2021, an increase of $661,600, or approximately 9%. The performance of all our business segments for the nine-month period is discussed in further detail below.

The following table presents a period-to-period comparison of total revenue by segment for the nine months ended September 30, 2022 and September 30, 2021:

Gross profit for the nine-month period ended September 30, 2022 was $4,560,816, compared to $4,360,266, for the same period in 2021. This represents an increase of $200,550 or approximately 5%.

The following table presents cost of sales and gross profit data for each of our business segments for the nine months ended September 30, 2022 and 2021:

Operating expenses were $5,762,521 for the nine-month period ended September 30, 2022, compared to $4,794,650 for the same period in 2021. This represents an increase of $967,871, or approximately 20%. This increase is primarily due to an approximate 30% increase in Salaries and Contract Labor costs and a 142% increase in Research and Development costs. The increase in Salaries and Contract Labor costs is a result of increased equity-based compensation and increases to labor rates incurred during the nine months ended September 30, 2022, as compared to the same period in 2021. The increase in Research and Development cost is due to increased activity in product development during the nine months ended September 30, 2022, as compared to the same period in 2021.

The following table shows total operating expenses for the nine-month period ended September 30, 2022 and 2021:

Other income was $2,077,719 for the nine months ended September 30, 2022, as compared to $229,559 for the same period in 2021. This is an increase of $1,848,160, or approximately 805%, primarily due to a $1,797,978 gain on sale of assets to Pharmalogic Idaho, LLC. In February 2022, we entered into an Asset Purchase Agreement with Pharmalogic Idaho, LLC, pursuant to which we sold certain assets for $4,000,000 in cash. The assets consisted primarily of manufacturing equipment and a sublease acquired by the Company in connection with the previously announced termination of the manufacturing and supply agreement with another company.

Interest expense for the nine months ended September 30, 2022 was $465,260, compared to $601,291 for the same period in 2021. This is a decrease of $136,031, or approximately 23%. Interest expense includes dividends accrued on our Series C Preferred Stock. For the nine months ended September 30, 2022, we accrued dividends payable of $182,835 which have been recorded as interest expense. Additionally, non-cash interest expense in the amount of $79,644 for the accretion of the beneficial conversion feature of the 2019 Promissory Note and $112,555 for the issuance of warrants in conjunction with the 2019 Promissory Note were recorded for the nine months ended September 30, 2022. See Note 7 “Debt” to our unaudited consolidated financial statements in this Quarterly Report for additional information about our indebtedness and the associated interest expense.

Our net income for the nine months ended September 30, 2022, was $414,328, compared to net loss of $919,408, for the same period in 2021. This is an increase in income of $1,333,736 is largely the result of the approximate $1.8 million gain on sale of assets. Additionally, the increase in income is the result of the increase in revenue in our Radiochemical Products segment offset by the increase in operating expense from salaries and contract labor and expenses from research and development for the nine months ended September 30, 2022, as compared to the same period in 2021.

Radiochemical Products. Revenue from the sale of Radiochemical Products for the nine-month period ended September 30, 2022, was $4,304,629 compared to $3,100,001 for the same period in 2021. This is an increase of $1,204,628, or approximately 39%. The increase is the result of increased sales to most of our customers and further enhanced by a reduction in sales by our competitor in the first quarter of 2022. The reduction in sales by our competitor resulted from a short-term shutdown of a European reactor facility that normally supplied their sodium iodide I-131 during the first quarter of 2022. The increase is also the result of increased sales of our new generic sodium iodide I-131 drug product. We expect continued sales growth for our Radiochemical Products going forward.

Cost of sales was $1,567,097 for the nine-month period ended September 30, 2022, and $1,251,953 for the same period in 2021. This is an increase of $315,144, or approximately 25%. This increase is primarily the result increased sales for the period.

Gross profit percentages for our Radiochemical Products for the nine months ended September 30, 2022 and 2021 were approximately 64% and 60%, respectively. This increased gross profit percentage is a result of increased sales of our new generic sodium iodine I-131 drug product, which carries a higher gross margin, and continued improvements of utilization of raw materials. Operating expense for this segment for the nine-month period ended September 30, 2022 was $1,104,994, compared to $1,068,580 for the same period in 2021. This is an increase of $36,414, or approximately 3%, and is primarily due to increased costs for labor costs, production supplies, advertising expense, and professional services. As discussed above, other income from the Radiochemical Products segment included a $1,797,978 gain on sale of manufacturing equipment and a sublease acquired by the Company in connection with the previously announced termination of the manufacturing and supply agreement with another company. Net income for this segment increased to $3,430,516 for the nine-month period ended September 30, 2022, from $779,468 for the same period in 2021. This increase of $2,651,048, or approximately 340%, is the result of the gain on sale of assets and the 39% increase in revenue.

Cobalt Products. Revenues from the sale of Cobalt Products for the nine-month period ended September 30, 2022 were $695,783, compared to $1,104,176 for the same period in 2021. This is a decrease of $408,393, or approximately 37%, and is the result of decreased cobalt sealed source manufacturing and cobalt recycling. The decrease was primarily due to the timing of cobalt sealed source manufacturing sales. Large value sales of high activity cobalt sources occur at somewhat random times throughout the year. Frequently the timing of these sales can have a significant impact on period over period comparisons.

During 2015, we entered into cobalt-60 supply agreements with several customers. The terms of the agreements required pre-payments to secure cobalt material in future years. Those prepayments were recorded as unearned revenue on our condensed consolidated balance sheet.

Cost of sales for the nine months ended September 30, 2022, was $315,204, as compared to $456,056, for the same period in 2021. Gross profit for cobalt products for the nine months ended September 30, 2022 was $380,579 compared to $648,120 for the same period in 2021. This is a decrease of $267,541, or 41%. Our gross profit percentages were approximately 55% and 59% for the nine-month periods ended September 30, 2022 and 2021, respectively. Operating expense in this segment increased to $570,030 for the nine months ended September 30, 2022, from $302,828 for the same period in 2021. This is an increase of $267,202, or approximately 88% is mainly the result of approximately $215,000 of waste disposal expenses in 2022 as compared to no such expense in 2021. Additionally, increased labor expenses and production supply costs contributed to the increase in operating expenses in the nine months ended September 30, 2022 as compared to the same period in 2021. Our net loss for Cobalt Products was $189,451 for the nine months ended September 30, 2022, as compared to a net income of $345,292 for the same period in 2021. The decrease in net income of $534,743 or approximately 155%, was attributable to the decreased cobalt sealed source manufacturing sales and increased operating expenses for the nine months ended September 30, 2022, as compared to the same period in 2021.

Nuclear Medicine Standards. Revenue from Nuclear Medicine Standards for the nine-month period ended September 30, 2022 was $3,031,110 compared to $3,135,970 for the same period in 2021. This represents a decrease in revenue attributable to this segment of $104,860, or approximately 3%. The decrease in sales for the period ended September 30, 2022 was due partly to continued slow demand of nuclear medicine imaging products resulting from the continued adverse impact of COVID-19 upon our customers and clinics during the nine months ended September 30, 2022.

Gross profit for the nine-month period ended September 30, 2022 was $1,442,705, as compared to $1,834,323 for the same period in 2021, a decrease of $391,618, or approximately 21%. Operating expense for this segment for the nine-month period ended September 30, 2022 increased to $1,365,962, from $1,327,733 for the same period in 2021. This is an increase of $38,229 or approximately 3% and is the result of increased waste disposal costs in the nine months ended September 30, 2022. Operating expenses include consolidated non-controlling member interest expense of $0 for the nine months ended September 30, 2022, compared to $116,816, for the nine months ended September 30, 2021. Net income for this segment for the nine-month period ended September 30, 2022, decreased to $76,743, approximately 85%, from $506,590 for the same nine-month period in 2021. This decrease is due to increased costs for supplies and raw materials attributable to cost inflation.

In January 2020, we notified our gemstone processing customer that the service contract with them was being terminated because the volume of gemstones sent for processing did not meet contract minimums. The termination activities and wrap up of this service substantially occurred in 2021 and the Company saw a steady decline in revenue from this service as production was wrapped up. In the first half of 2022, we have converted the spaces in the facility that had been used to perform this contract work into expanded Nuclear Medicine new product manufacturing. The loss in revenue expected from termination of the gemstone processing agreement is expected to be more than compensated for by the expansion of new nuclear medicine source products.

Revenue from field service work for the DOE had accounted for the majority of revenue in this segment. However, Radiological Field Services did not generate any Radiological Services segment sales in 2022 or 2021. This was the result the removal of this activity from our NRC license.

Fluorine Products. For the nine months ended September 30, 2022, we had no revenue related to Fluorine Products compared to $29,775, for the same period in 2021. These revenues were related to an agreement to provide engineering and technical assistance services related to our fluorine products intellectual property. During the nine months ended September 30, 2022, we incurred $111,377 of expenses related to items in support of future planning and design for the proposed de-conversion facility, as compared to $121,500 for the same nine-month period in 2021. This is a decrease of 8% in the period-to-period comparison.

We established the Fluorine Products segment in 2004 to support production and sale of the gases produced using our Fluorine Extraction Process (“FEP”). We will continue to limit our expenditures to essential items such as maintenance of the NRC license, land use agreements, communication with our prospective FEP product customers, and interface with the State of New Mexico and Lea County officials.

At September 30, 2022, we had cash and cash equivalents of $2,989,236 as compared to $474,851 at December 31, 2021. This is an increase of $2,514,385 or approximately 530%. For the nine months ended September 30, 2022, net cash used in operating activities was $957,163 and for the nine months ended September 30, 2021, net cash provided by operating activities was $64,294. The increase in cash used in operating activities was a result of increased accounts receivable due to increased revenue. The increase in cash and cash equivalents at period end in the period-to-period comparison is the result of proceeds from sales of property, plant, and equipment.

Inventories at September 30, 2022 totaled $879,210, and inventories at December 31, 2021 totaled $924,775. Our inventory consists of work in process material for our Radiochemical Products, Cobalt Products, and Nuclear Medicine Products segments.

Cash provided by investing activities was $3,931,725 for the nine months ended September 30, 2022, and cash used in investing activities was $196,730 for the same period in 2021. The cash provided by investing activities in the nine months ended September 30, 2022 was mainly for the sale of assets for $4,000,000. In February 2022, we entered into an Asset Purchase Agreement with Pharmalogic Idaho, LLC, pursuant to which we sold certain assets for $4,000,000 in cash. The Assets consisted primarily of manufacturing equipment and a sublease acquired by the Company in connection with the previously announced termination of the manufacturing and supply agreement with another company. The cash used in investing activities in the nine months ended September 30, 2021 was for purchase of equipment.

Financing activities used cash of $456,759, during the nine months ended September 30, 2022, and cash used in financing activities for the same period in 2021 was $34,994. During the nine months ended September 30, 2022, cash paid for interest was $49,699 and during the same nine-month period in 2021, cash paid for interest was $69,042. Additionally, during the nine months ended September 30, 2022, we received $12,305 in proceeds from the sale of our common stock through our Employee Stock Purchase Plan and $61,800 for exercise of warrants, as compared to $13,527 in proceeds from the sale of our common stock through our Employee Stock Purchase Plan for the same period in 2021. During the nine months ended September 30, 2022, principal payments on notes payable were $524,532, as compared to $390,571 for the same period in 2021. This increase in principal payments was largely due to payment in full of the 2021 Promissory Note as described below.

In February 2022, the Company paid its third annual dividend on the Series C Preferred Stock. Dividends paid totaled $243,780. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company’s common stock in lieu of cash. The Company issued 2,271,980 shares of common stock in lieu of a dividend payment of $204,480. The remaining $39,300 of dividend payable was settled with cash.

Total increase in cash for the nine-month period ended September 30, 2022, was $2,517,803 compared to a cash decrease of $167,430 for the same period in 2021.

We expect that cash from operations, cash raised via equity financing, and our current cash balance will be sufficient to fund operations for the next twelve months. Our future liquidity and capital funding requirements will depend on numerous factors, including, contract manufacturing agreements, commercial relationships, technological developments, market factors, available credit, and preferred stock shareholders. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

At September 30, 2022, there were no outstanding warrants to purchase our common stock.

In December 2013, we entered into a promissory note agreement with our then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $500,000 (the 2013 Promissory Note). The 2013 Promissory Note is secured and bears interest at 6% per annum and was originally due June 30, 2014. According to the terms of the 2013 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of our common stock. In June 2014, pursuant to a modification, the maturity date was extended to December 31, 2017. In February 2017, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2020, with all remaining terms unchanged. In December 2019, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2021, with all remaining terms unchanged. In January 2022, the 2013 Promissory Note was modified to extend the maturity date to December 31, 2023, with all remaining terms unchanged. At September 30, 2022, accrued interest payable on the 2013 Promissory Note totaled $264,234.

In April 2018, we borrowed $120,000 from our Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note). The 2018 Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the 2018 Promissory Note. The 2018 Promissory Note was originally unsecured and originally matured on August 1, 2018. At any time, the holder of the 2018 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. Pursuant to an amendment to the 2018 Promissory Note in June 2018, the maturity date was extended to March 31, 2019 with all other provisions remaining unchanged. Pursuant to a second amendment to the 2018 Promissory Note in February 2019, the maturity date was extended to July 31, 2019 with all other provisions remaining unchanged. Pursuant to a third amendment to the 2018 Promissory Note in July 2019, the maturity date was extended to January 31, 2020 with all other provisions remaining unchanged. Pursuant to a fourth amendment to the 2018 Promissory Note in December 2019, the maturity date was extended to December 31, 2021, the note was modified to become secured by company assets, with all other provisions remaining unchanged. In December 2021, the 2018 Promissory Note was modified to extend the maturity date to December 31, 2023, with all remaining terms unchanged. At September 30, 2022, accrued interest on the 2018 Promissory Note totaled $31,970.

In December 2019 and February 2020, we borrowed $1,000,000 from our Chief Executive Officer, Chairman of the Board, former Chairman of the Board, and one of our major shareholders pursuant to a promissory note (the 2019 Promissory Note). The 2019 Promissory Note bears an interest rate of 4% annually and is due December 31, 2022. According to the terms of the 2019 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of the Company’s common stock based on the average closing price of the Company’s common stock for the 20 days preceding the payment. At September 30, 2022, the balance of the 2019 Promissory Note was $1,000,000, The remaining debt discount was $37,518, the remaining beneficial conversion feature was $26,548, and the accrued interest on the 2019 Promissory Note totaled $109,131.

In April 2021, we borrowed $250,000 from its Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2021 Promissory Note). The 2021 Promissory Note accrued interest at 6% per annum, which was payable upon maturity of the 2021 Promissory Note. The 2021 Promissory Note was originally secured and was to mature on December 31, 2022. At any time, the holders of the 2021 Promissory Note were able to elect to have any or all of the principal and accrued interest settled with shares of our common stock at a conversion price of $0.11 per share. On March 31, 2022, the Company repaid the 2021 Promissory Note in full. The payment included $250,000 in principal and $14,500 in interest.

From time-to-time, management reviews and evaluates certain accounting policies and estimates that are considered to be significant in determining our results of operations and financial position.

A description of the Company’s critical accounting policies and estimates that affect the preparation of the Company’s financial statements is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022.

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), that are designed to ensure that material information relating to us is made known to the officers who certify our financial reports and to other members of senior management and the Board of Directors. These disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports that are filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness, as of September 30, 2022, of our disclosure controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2022.

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

A discussion of legal matters is found in Note 8, “Commitments and Contingencies”, in the accompanying notes to the unaudited condensed consolidated financial statements included in Part I - Item 1. Financial Statements of this Quarterly Report.

There have been no material changes or updates to the risk factors previously disclosed in Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Large accelerated filer ¨	Accelerated filer ¨
i Non-accelerated filer ý	Smaller reporting company i x

	Emerging growth company i ¨

	September 30,			December 31,
	2022			2021
Assets
Current assets
Cash and cash equivalents	$	i 2,989,236		$	i 474,851
Accounts receivable		i 1,542,711			i 853,675
Inventories		i 879,210			i 924,775
Prepaids and other current assets		i 891,681			i 1,004,423
Total current assets		i 6,302,838			i 3,257,724

Long-term assets
Restricted cash		i 834,170			i 830,752
Property, plant and equipment, net		i 2,011,513			i 4,299,937
Capitalized lease disposal costs, net		i 232,781			i 246,748
Financing lease right-of-use asset		i 14,124			i 18,631
Operating lease right-of-use asset		i 2,341,495			i 2,429,622
Goodwill		i 1,384,255			i 1,384,255
Patents and other intangibles, net		i 3,744,577			i 3,859,473
Total long-term assets		i 10,562,915			i 13,069,418
Total assets	$	i 16,865,753		$	i 16,327,142

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	i 1,181,199		$	i 1,424,028
Accrued liabilities		i 1,230,248			i 1,189,165
Unearned revenue		i 908,843			i 907,953
Current portion of operating lease right-of-use liability		i 129,376			i 121,069
Current portion of financing lease liability		i 6,981			i 8,542
Current portion of related party notes payable, net of debt discount		i 935,934			i 993,735
Current installments of notes payable		i 36,253			i 290,017
Current portion of mandatorily redeemable preferred stock, net of debt discount		i 4,063,000			—
Total current liabilities		i 8,491,834			i 4,934,509

Long-term liabilities
Accrued long-term liabilities		i 121,875			—
Related party notes payable, net of current portion and debt discount		i 620,000			i 620,000
Notes payable, net of current portion		i 37,001			i 57,769
Asset retirement obligation		i 929,545			i 892,086
Financing lease liability, net of current portion		i 3,575			i 8,346
Operating lease right-of-use liability, net of current portion		i 2,265,972			i 2,363,815
Mandatorily redeemable convertible preferred stock, net of current portion and discount		—			i 4,719,822
Total long-term liabilities		i 3,977,968			i 8,661,838
Total liabilities		i 12,469,802			i 13,596,347

Stockholders' equity
Common stock, $ i i 0.01 / par value; i i 750,000,000 / shares authorized; i i 514,817,369 / and i i 502,584,176 / shares issued and outstanding respectively		i 5,148,174			i 5,025,842
Additional paid in capital		i 125,597,530			i 124,469,034
Accumulated deficit		( i 126,349,753	)		( i 126,764,081	)
Total equity		i 4,395,951			i 2,730,795
Total liabilities and stockholders' equity	$	i 16,865,753		$	i 16,327,142


	Nine months ended September 30,
	2022			2021
Cash flows from operating activities
Net (loss) income	$	i 414,328		$	( i 806,021	)
Adjustments to reconcile net (loss) income to net Cash provided by operating activities
Depreciation and amortization		i 288,047			i 440,718
Accretion of obligation for lease disposal costs		i 37,459			i 31,119
Accretion of beneficial conversion feature and discount		i 210,377			i 301,575
Equity based compensation		i 297,243			i 60,671
Gain on sale of property, plant, and equipment		( i 1,797,978	)		—
Right-of-use asset amortization		( i 1,409	)		i 19,260
Changes in operating assets and liabilities:
Accounts receivable		( i 689,036	)		( i 247,593	)
Inventories		i 45,565			i 255,489
Prepaids and other current assets		i 112,742			i 931,953
Accounts payable and accrued liabilities		i 124,609			( i 789,406	)
Unearned revenues		i 890			( i 133,471	)
Net cash provided by operating activities		( i 957,163	)		i 64,294

Cash flows from investing activities:
Proceeds from sale of property, plant and equipment		i 4,000,000			—
Purchase of property, plant, and equipment		( i 68,275	)		( i 196,730	)
Net cash (used in) provided in investing activities		i 3,931,725			( i 196,730	)

Cash flows from financing activities:
Proceeds from sale of stock and exercise of options and warrants		i 74,105			i 13,527
Payments on financing lease		( i 6,332	)		( i 5,772	)
Distributions to non-controlling interest		—			( i 3,431	)
Proceeds from the issuance of notes payable		—			i 351,253
Principal payments on notes payable		( i 524,532	)		( i 390,571	)
Net cash used in financing activities		( i 456,759	)		( i 34,994	)

Net (decrease) increase in cash, cash equivalents, and restricted cash		i 2,517,803			( i 167,430	)
Cash, cash equivalents, and restricted cash at beginning of period		i 1,305,603			i 1,751,692
Cash, cash equivalents, and restricted cash at end of period	$	i 3,823,406		$	i 1,584,262

Supplemental disclosure of cash flow activities:
Cash paid for interest	$	i 49,699		$	i 69,042

Supplemental disclosure of noncash financing and investing transactions
Decrease in accrued interest and increase in equity for conversion of dividends to stock	$	i 204,480		$	i 207,480
Increase in operating lease right-of-use asset and right-of-use liability for new lease	$	—		$	i 1,603
Increase in equity and decrease in liability for the conversion of preferred stock	$	i 675,000		$	i 325,000
Non-cash increase of capitalized ARO for increased funding plan	$	—		$	i 260,715
Decrease in unearned revenue and increase in notes payable for repayment plan	$	—		$	i 146,072
Increase in equity and decrease in Non-controlling interest for acquisition of non controlling interest in RadQual and TI Services	$	—		$	i 2,423,662

	September 30,		September 30,
	2022		2021
Cash and cash equivalents	$	i 2,989,236	$	i 753,526
Restricted cash included in long-term assets		i 834,170		i 830,736
Total cash, cash equivalents, and restricted cash shown in statement of cash flows	$	i 3,823,406	$	i 1,584,262

Series B Redeemable Convertible Preferred Stock
Series C Redeemable Convertible Preferred Stock	September 30,
	2022		2021
Stock options		i 24,868,500		i 21,102,500
Warrants		—		i 7,065,000
Shares of Series B redeemable convertible preferred stock		—		i 337,500
Shares of Series C redeemable convertible preferred stock		i 40,630,000		i 40,630,000
		i 65,498,500		i 69,135,000

International Isotopes Inc. – ‘10-Q’ for 9/30/22

On: Monday, 11/14/22, at 3:24pm ET · For: 9/30/22 · Accession #: 1515971-22-184 · File #: 0-22923

Previous ‘10-Q’: ‘10-Q’ on 8/15/22 for 6/30/22 · Next: ‘10-Q’ on 5/15/23 for 3/31/23 · Latest: ‘10-Q’ on 5/15/24 for 3/31/24 · 4 References:

Quarterly Report — Form 10-Q

Filing Table of Contents

‘10-Q’ — Quarterly Report

Document Table of Contents

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

4 Previous Filings that this Filing References

		Page No.
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements
	Unaudited Condensed Consolidated Balance Sheets at September 30, 2022 and December 31, 2021	3
	Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2022 and 2021	4
	Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021	5
	Unaudited Statement of Reconciliation of Stockholder’s (Deficit) Equity for the Three and Nine Months Ended September 30, 2022 and 2021	6
	Notes to Unaudited Condensed Consolidated Financial Statements	8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	17
Item 4.	Controls and Procedures	27

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 6.	Exhibits	28
Signatures		29

	September 30, 2022		December 31, 2021
Radiochemical Products	$	i 39,900	$	i 79,747
Cobalt Products		i 391,899		i 441,749
Nuclear Medicine Products		i 447,411		i 403,279
	$	i 879,210	$	i 924,775

	Operating			Financing
2022 (excluding the nine-months ended September 30, 2022)	$	i 71,777		$	i 2,410
2023		i 287,108			i 5,881
2024		i 287,108			i 2,929
2025		i 287,108			i —
2026		i 287,108			i —
Thereafter		i 2,312,301			i —
Total minimum operating lease obligations		i 3,532,510			i 11,220
Less-amounts representing interest		( i 1,137,162	)		( i 664	)
Present value of minimum operating lease obligations		i 2,395,348			i 10,556
Current maturities		( i 129,376	)		( i 6,981	)
Lease obligations, net of current maturities	$	i 2,265,972		$	i 3,575

	September 30,		December 31,
Segment Assets	2022		2021
Radiochemical Products	$	i 890,369	$	i 2,890,590
Cobalt Products		i 697,752		i 597,420
Nuclear Medicine Standards		i 1,476,708		i 2,259,759
Fluorine Products		i 5,176,296		i 5,258,823
Total Segments		i 8,241,125		i 11,006,592
Corporate assets		i 8,624,628		i 5,320,550
Total Consolidated	$	i 16,865,753	$	i 16,327,142

	For the three- months ended September 30,		For the three- months ended September 30,
Sale of Product	2022		2021		$ change			% change
Radiochemical Products	$	1,298,667	$	1,210,615	$	88,052			7	%
Cobalt Products		424,731		408,808		15,923			4	%
Nuclear Medicine Standards		1,065,875		990,328		75,547			8	%
Fluorine Products		—		7,763		(7,763	)		-100	%
Total Consolidated	$	2,789,273	$	2,617,514	$	171,759

	For the three- months ended September 30,			% of Total Sales			For the three- months ended September 30,			% of Total Sales
	2022			2022			2021			2021
Total Sales	$	2,789,273					$	2,617,514
Cost of Sales
Radiochemical Products	$	498,210			18	%	$	459,344			17	%
Cobalt Products		232,679			8	%		148,855			6	%
Nuclear Medicine Standards		574,841			21	%		398,135			15	%
Fluorine Products		—			0	%		—			0	%
Total Segments		1,305,730			47	%		1,006,334			38	%

Gross Profit	$	1,483,543					$	1,611,180
Gross Profit %		53	%					62	%

	For the three- months ended September 30,		For the three- months ended September 30,
Operating Costs and Expenses:	2022		2021		% change			$ change
Salaries and Contract Labor	$	800,550	$	650,065		23	%	$	150,485
General, Administrative and Consulting		1,008,219		885,807		14	%		122,412
Research and Development		148,327		73,886		101	%		74,441
Total operating expenses	$	1,957,096	$	1,609,758		22	%	$	347,338

	For the nine- months ended September 30,		For the nine- months ended September 30,
Sale of Product	2022		2021		$ change			% change
Radiochemical Products	$	4,304,629	$	3,100,001	$	1,204,628			39	%
Cobalt Products		695,783		1,104,176		(408,393	)		-37	%
Nuclear Medicine Standards		3,031,110		3,135,970		(104,860	)		-3	%
Fluorine Products		—		29,775		(29,775	)		0	%
Total Consolidated	$	8,031,522	$	7,369,922	$	661,600

Date: November 14, 2022	International Isotopes Inc.


	By:	/s/ *Steve T. Laflin*
		Steve T. Laflin
		President and Chief Executive Officer


	By:	/s/ *W. Matthew Cox*
		W. Matthew Cox
		Chief Financial Officer

This ‘10-Q’ Filing	Date	Other Filings

	9/30/24
	12/31/23
	12/15/23
	2/17/23
	12/31/22
Filed on:	11/14/22
	11/11/22
For Period end:	9/30/22
	7/1/22
	5/31/22
	5/12/22
	3/31/22	10-K, 10-Q
	2/28/22
	2/22/22	8-K
	2/21/22	4
	2/17/22
	2/14/22
	1/1/22
	12/31/21	10-K
	9/30/21	10-Q
	7/8/21	8-K
	7/1/21
	6/2/21
	2/28/21
	1/1/21
	12/31/20	10-K
	1/31/20
	7/31/19
	3/31/19	10-Q
	8/1/18
	12/31/17	10-K
	2/24/17	8-K
	12/31/16	10-K
	12/31/15	10-K
	12/31/14	10-K
	10/1/14
	6/30/14	10-Q, 4
	6/30/10	10-Q
	5/1/97	SB-2
		List all Filings